急性移植物抗宿主病复发:西奈山急性GVHD国际联盟分析
该研究回顾性评估了23个MAGIC移植中心968例在治疗4周内达到完全缓解或极好部分缓解的患者,6个月内GVHD复发累积发生率为22%,复发与更高的非复发死亡风险相关(aHR 4.84)。复发时病情更重且下消化道受累更常见,CR/VGPR时MAGIC生物标志物可预测未来复发及其严重程度。
要点
- GVHD复发6个月累积发生率为22%,与NRM风险升高相关(aHR 4.84)
- 复发时3/4级比例高于初发GVHD(41% vs 16%),下消化道受累更常见(55% vs 32%)
- CR/VGPR时AA2 vs AA1的aHR为1.81,AA3 vs AA1的aHR为3.14,可预测复发
核心结论
- GVHD复发常见且携带显著死亡风险,未来复发可通过血清生物标志物预测,可能有助于指导免疫抑制的调整与停用。
研究设计与样本
- 回顾性评估23个西奈山急性GVHD国际联盟(MAGIC)移植中心的968例患者,均为治疗4周内达到完全缓解(CR)或极好部分缓解(VGPR)者。
主要发现
- 6个月内复发累积发生率为22%,复发与更高的非复发死亡(NRM)风险相关(aHR 4.84;95%CI 3.19-7.36;P<.001)。
- 复发较初发GVHD更严重(3/4级:41% vs 16%;P<.001)且下消化道受累更频繁(55% vs 32%;P<.001)。
- CR/VGPR时AA2 vs AA1的aHR为1.81(95%CI 1.32-2.48;P=.001),AA3 vs AA1的aHR为3.14(95%CI 1.98-4.98;P<.001)。
- 初始治疗早期应答的aHR为1.84(95%CI 1.21-2.80;P=.004),HLA不合无关供者的aHR为1.74(95%CI 1.00-3.02;P=.049)。
- MAGIC生物标志物在CR/VGPR时和复发时均可对NRM风险进行分层。
临床怎么用
- 作者认为,血清生物标志物可预测未来GVHD复发,可能有助于指导免疫抑制的调整与停用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consortium (MAGIC) transplant centers who achieved complete response (CR) or very good partial response (VGPR) within 4 weeks of treatment. The cumulative incidence of flares within 6 months was 22%, and flares were associated with a higher risk of nonrelapse mortality (NRM; adjusted hazard ratio [aHR], 4.84; 95% confidence interval [CI], 3.19-7.36; P < .001). Flares were more severe (grades 3/4, 41% vs 16%; P < .001) and had more frequent lower gastrointestinal (LGI) involvement (55% vs 32%; P < .001) than the initial GVHD. At CR/VGPR, elevated MAGIC biomarkers predicted the future occurrence of a flare, along with its severity and LGI involvement. In multivariate analyses, higher Ann Arbor (AA) biomarker scores at CR/VGPR were significant risk factors for flares (AA2 vs AA1: aHR, 1.81 [95% CI, 1.32-2.48; P = .001]; AA3 vs AA1: aHR, 3.14 [95% CI, 1.98-4.98; P < .001]), as were early response to initial treatment (aHR, 1.84; 95% CI, 1.21-2.80; P = .004) and HLA-mismatched unrelated donor (aHR, 1.74; 95% CI, 1.00-3.02; P = .049). MAGIC biomarkers also stratified the risk of NRM both at CR/VGPR and at the time of flare. We conclude that GVHD flares are common and carry a significant mortality risk. The occurrence of future flares can be predicted by serum biomarkers that may serve to guide adjustment and discontinuation of immunosuppression.
引用
- Akahoshi Y, Spyrou N, Hoepting M, et al. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. Blood Adv. 2024. PMID: 38324721. doi:10.1182/bloodadvances.2023012091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。